Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onabotulinum Toxin A for Myospasm-Related Masticatory Muscle Disorder
NCT06840730Completed
- Sponsor
- Hacettepe University
- Start
- Jun 2024
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in masticatory muscle disorder (MMM), sponsored by Hacettepe University. Primary endpoint: Change in Pain Intensity at 28 days. Started Jun 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
masticatory muscle disorder (MMM)
Beyond the preview
Go deeper on NCT06840730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840730.